Brief: Tricida Reports Topline Results From The Valor-Ckd Phase 3 Trial Of Veverimer

Tricida

24/10/2022 13:51

Oct 24 (Reuters) - Tricida Inc  TCDA.O :
    * TRICIDA REPORTS TOPLINE RESULTS FROM THE VALOR-CKD PHASE 3
TRIAL
OF VEVERIMER
    * TRICIDA INC - VALOR-CKD TRIAL DID NOT MEET ITS PRIMARY
ENDPOINT
    * TRICIDA INC - PRESPECIFIED HIERARCHICAL ANALYSIS DID NOT
PERMIT
STATISTICAL TESTING OF SECONDARY ENDPOINTS
    * TRICIDA - SAFETY PROFILE OF VEVERIMER IN PART A AND B OF
TRIAL
CONSISTENT WITH THAT EXPECTED FOR GENERAL POPULATION OF PATIENTS
WITH STAGE 3 TO 5 CKD

Source text for Eikon:  ID:nBw81mksva 
Further company coverage:  TCDA.O 
 ((Reuters.Briefs@thomsonreuters.com;))